Prot #GB002-3101: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

Project: Research project

Project Details

StatusActive
Effective start/end date3/12/24 → 3/12/27

Funding

  • PPD Investigator Services, LLC (Prot #GB002-3101 // Prot #GB002-3101)
  • GB002, Inc. (Prot #GB002-3101 // Prot #GB002-3101)